Profile of selumetinib and its potential in the treatment of melanoma
Dae Won Kim, Sapna P Patel
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Abstract: The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver signal in a number of malignancies. The discovery of activating mutations in the MAPK pathway has led to the development of MAPK pathway inhibitors. Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, which are essential downstream molecules in the MAPK pathway. Several preclinical and clinical studies have demonstrated the promising antitumor activity of selumetinib. In this review, we discuss the MAPK pathway in melanoma and summarized data from preclinical and clinical studies of selumetinib for advanced melanoma.
Keywords: selumetinib, MEK inhibitor, melanoma, uveal melanoma